
GRI Stock Forecast & Price Target
GRI Analyst Ratings
Bulls say
GRI Bio is a clinical-stage biotech company with a focus on discovering and developing therapies for dysregulated immune responses. The company's two product candidates, GRI-0621 and GRI-0803, have shown promising results in treating serious diseases associated with inflammatory, fibrotic, and autoimmune disorders. With a large market potential for its treatment of idiopathic pulmonary fibrosis, positive top-line data, and a prime location in La Jolla, CA, GRI Bio presents a positive outlook for its long development and commercialization roads, despite the inherent risks of clinical trials and commercial failures.
Bears say
GRI Bio is a clinical stage biotech company with a negative EPS of $(13.30) and no Q4 guidance. Its main focus is the development of GRI-0621 for the treatment of IPF, with other product GRI-0803 targeting potential autoimmune disorders. The company's recent financial results and history of preclinical work in SLE and MS indicate potential risks and uncertainties, leading to the negative outlook and a revised 12-month price target of $36 (based on NPV analysis).
This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GRI Analyst Forecast & Price Prediction
Start investing in GRI
Order type
Buy in
Order amount
Est. shares
0 shares